Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01178112 · ClinicalTrials.gov registry record · Phase 1
Trientine and Carboplatin in Advanced Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01178112: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01178112 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 56 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01178112, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of trientine and carboplatin that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
Primary Outcome
MTD defined by dose limiting toxicities (DLTs) that occur in the first cycle (4 weeks). DLT defined as treatment-related grade 3 or greater nonhematological toxicity other than nausea, vomiting, or fatigue.
Interventions
- DRUG Carboplatin
- DRUG Trientine
- DRUG Trientine MTD
- DRUG Carboplatin MTD
- OTHER PK Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
What the finished NCT01178112 record still lists
NCT01178112 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01178112 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01178112 about?
NCT01178112 is a clinical study titled "Trientine and Carboplatin in Advanced Malignancies". The goal of this clinical research study is to find the highest tolerable dose of the combination of trientine and carboplatin that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
What is the current status of trial NCT01178112?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2010-07. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01178112?
The interventions under investigation include: Carboplatin (DRUG), Trientine (DRUG), Trientine MTD (DRUG), Carboplatin MTD (DRUG), PK Testing (OTHER).
Who is sponsoring clinical trial NCT01178112?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01178112's enrollment target sits among peer trials
56 902nd of 2000 higher than 1,083 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia